Drugs / Indium In-111 Ibritumomab Tiuxetan
Indium In-111 Ibritumomab Tiuxetan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00012298 | Apr 2001 → Apr 2010 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, nodal marginal zone B-cell lymphoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01434472 Background | Nov 2011 → May 2020 | Burkitt lymphoma, diffuse large B-cell lymphoma, post-transplant lymphoproliferative disease | Fred Hutchinson Cancer Center | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indium In 111 ibritumomab tiuxetan | “Indium In-111 Ibritumomab Tiuxetan” NCT01434472 ↗ |
| Known as | 111indium-zevalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108610 ↗ |
| Known as | Zevalin indium in-111 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108610 ↗ |
| Modality | Monoclonal antibody | — CHEMBL2108610 ↗ |
| Route | Intravenous | “indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1” NCT00012298 ↗ |